Virginia 2024 Regular Session

Virginia House Bill HB1187

Introduced
1/10/24  
Refer
1/10/24  
Report Pass
2/7/24  
Engrossed
2/12/24  
Refer
2/14/24  
Report Pass
2/21/24  
Report Pass
2/28/24  
Enrolled
3/7/24  
Chaptered
4/4/24  

Caption

Xylazine; penalty for manufacturing, selling, etc., for human consumption.

Impact

The implementation of HB 1187 will significantly alter the legal approach to substances like xylazine within Virginia's drug laws. By establishing clear penalties for its misuse, the bill seeks to deter potential offenders and address public health concerns associated with its consumption. Furthermore, the bill maintains allowances for veterinary use, ensuring that legitimate practices in animal healthcare are not adversely affected. The bill's enactment suggests a proactive stance against the increasing challenges posed by substance misuse and aims to protect public health and safety.

Summary

House Bill 1187 addresses the manufacturing, selling, and possession of the substance xylazine when intended for human consumption. The bill introduces serious penalties for those found guilty of violating its provisions. Specifically, individuals who manufacture, sell, give, distribute, or possess xylazine with the intent for human use would be charged with a Class 5 felony, while simple possession intended for human consumption would be classified as a Class 1 misdemeanor. This legislative move aims to control and regulate the use of xylazine, particularly in light of its rising misuse in the community.

Sentiment

The sentiment surrounding HB 1187 appears to be largely supportive, particularly among those advocating for stronger regulation of potentially harmful substances. Policymakers and public health officials have viewed the bill as a crucial step towards enhancing community safety and minimizing the risks associated with unregulated substances. However, there may also be concerns regarding the implications of increased incarceration rates resulting from the felony classification. This nuanced perspective points to a tension between public safety goals and the potential social fallout of harsher penalties.

Contention

One point of contention regarding HB 1187 lies in the balance between enforcement and public health. While supporters contend that imposing strict penalties is necessary to curb the misuse of xylazine, critics may raise concerns about the impact of felony charges on individuals and communities, especially considering the broader implications for those with substance use disorders. Additionally, there may be discussions about the efficacy of punitive measures versus rehabilitation pathways, with some advocating for approaches that prioritize treatment over imprisonment.

Companion Bills

VA SB614

Similar To Xylazine; penalty for manufacturing, selling, etc., for human consumption.

Previously Filed As

VA HB1699

Minors; buying or selling, exceptions, penalties.

VA HB1682

Weapon of terrorism; definition, penalty.

VA SB1188

Weapon of terrorism; definition, penalty.

VA HB2240

Assault firearms, etc.; prohibiting sale, transport, penalties.

VA HB1455

Fentanyl; selling, giving, or distributing a substance that contains 2 mgms. or more, penalties.

VA HB1973

Industrial hemp; selling or offering for sale a topical hemp product, etc.

VA HB2273

Firearms; waiting period for purchase, penalty.

VA HB1464

Cannabis control; establishes framework for creation of retail market, transitional sale, penalties.

VA SB1284

Abortion; prohibited, exceptions, penalty.

VA SB1490

Fentanyl; selling, giving, or distributing a substance that contains 2 mgms. or more, etc.

Similar Bills

No similar bills found.